Erratum
In the article ‘Pharmacokinetic evaluation of ambrisentan’ published in the March 2011 issue of Expert Opinion on Drug Metabolism & Toxicology (Expert Opin Drug Metab Toxicol (2011) 7(3):371-380), an error has been spotted by the author since publication.
In Section 10.1 (Special patient populations), the sponsorship of the AMBITION study erroneously included United Therapeutics. The sponsors are Gilead and GlaxoSmithKline. The sentence in question should have read:
‘The role of upfront initiation of dual oral therapy will be evaluated in the upcoming AMBITION study co-sponsored by Gilead and GlaxoSmithKline.’
Informa Healthcare and the authors of this article would like to apologize for this error and for any confusion caused.
Addendum
On 11 February 2011, the FDA amended the black box warning for ambrisentan. In response to > 7000 patient-years of liver function data showing no excess in liver toxicity, monthly monitoring will no longer be required. Rather, monitoring will be at the discretion of the prescribing physician.